Canadian mail-order prescriptions face a new hurdle

For some Americans, Canada has served as a practical workaround to high prescription costs. That option is now facing a major new obstacle. A federal customs rule taking effect later this month is expected to make it harder for low-value packages from abroad to enter the United States, including medications mailed from Canadian pharmacies.

The change matters because it affects not just price, but access. People who have depended on cross-border mail-order prescriptions for routine medicines may see delays, added fees, or a stop to delivery altogether. Federal officials say the rule is aimed at customs enforcement, while patient advocates argue that it could interrupt access to lower-cost drugs for people who already struggle to pay for medicine.

What is changing

The rule targets the de minimis exemption, which previously let many shipments valued under $800 enter the country with less customs scrutiny. According to AP News, as of Oct. 22 that exemption will be suspended indefinitely, and medications mailed from outside the United States will need additional data and a bond guarantee. AP reported that the practical result could be more difficulty getting personal prescriptions delivered, even though the rule is not written specifically for Canadian drugs.

That distinction matters. The customs change is separate from the Food and Drug Administration’s formal importation pathway under section 804 of the Federal Food, Drug, and Cosmetic Act. FDA says that program allows states and Indian tribes to import certain prescription drugs from Canada to reduce costs without adding risk to public health and safety. In other words, a mail-order drug bought by an individual through a Canadian pharmacy is not the same thing as a state-run importation program that has gone through FDA review and authorization.

Why the issue is drawing attention

Drug affordability is already a central concern for many households, and AP reported that the customs change has drawn opposition from Democrats and some Republicans. The article also notes that President Donald Trump has made lowering prescription costs a policy priority, creating a tension between a cost-cutting message and a rule that could make some medicines less accessible.

For people who rely on imported prescriptions, the concern is straightforward: if the order cannot get through customs on time, a medication supply can run short. That is more than an inconvenience when a drug is taken daily for a chronic condition. AP quoted patients and advocates saying the change could lead to significant price increases or force people to look for a domestic alternative that may cost much more.

What the evidence actually shows

The strongest evidence here is about behavior and policy, not about a new drug treatment or a new medical risk. A 2020 JAMA Network Open study indexed in PubMed estimated that 1.5% of U.S. adults taking prescription medications, or about 2.3 million people, had purchased medication outside the United States. The study also found that people who purchased medications abroad were more likely to be older, have lower income, and be uninsured. That does not prove why any one person buys from abroad, but it does show that cross-border purchasing is not a fringe practice.

FDA’s own materials show that the agency has tried to create a tightly controlled importation pathway for states and tribes. The agency says these programs are meant to lower costs without adding risk to public health and safety, and its policy pages describe review, authorization, and quality-assurance steps. FDA also notes that it authorized Colorado’s importation program in June 2026 and has previously authorized Florida’s program. Those facts underscore that official importation is regulated and limited; it is not the same as a consumer placing an online order from abroad.

What remains uncertain

Several important questions are still unresolved. It is not yet clear how many individual patients will be affected, how quickly shipping problems will appear, or whether pharmacies and customs brokers will adapt in ways that soften the impact. It is also unclear how the rule will interact with the many different ways Americans obtain medicine from Canada, including mail order, courier delivery, and state importation arrangements.

Another open question is whether the rule will be enforced exactly as written or modified in response to political pressure. AP reported that lawmakers from both parties have asked the administration to explain how patients who depend on affordable imported medicines will be protected. That means the final effect on patients could depend as much on implementation as on the rule’s text.

What patients may want to watch

If you currently receive a medication by mail from a pharmacy outside the United States, this is a good time to check your refill timeline rather than wait for a shipment to stall. Ask the pharmacy whether it expects customs delays, whether extra paperwork will be needed, and whether there is a U.S.-based equivalent that can be filled locally. If the medicine is used to manage a chronic condition, do not let the supply run to zero before you raise the question.

It is also worth confirming the exact product and dose with a pharmacist or prescriber, especially if the drug is purchased from an international source. Package delays can create confusion about substitutions, labeling, and refill timing. For many people, the most important step is simply to plan ahead so a regulatory change does not become an abrupt interruption in treatment.

Bottom line

The new customs rule is not a clinical warning, but it is a health-access story. For some Americans, especially those who have turned to Canada because U.S. prices are too high, the policy could make already fragile access even less reliable. The public-health concern is not that the medicines themselves have changed. It is that the route to getting them may become harder, slower, and more expensive.

As the compliance date approaches, patients, pharmacies, and state officials will be watching to see whether the rule mainly affects shipping paperwork or whether it meaningfully disrupts access to medicines people already depend on.